Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.25
PRPH's Cash to Debt is ranked lower than
81% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. PRPH: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
PRPH' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: No Debt Max: No Debt
Current: 0.25
Equity to Asset 0.51
PRPH's Equity to Asset is ranked lower than
69% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.65 vs. PRPH: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
PRPH' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.73 Max: 0.96
Current: 0.51
0.48
0.96
F-Score: 3
Z-Score: 2.30
WACC vs ROIC
3.10%
-44.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -15.68
PRPH's Operating margin (%) is ranked lower than
80% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. PRPH: -15.68 )
Ranked among companies with meaningful Operating margin (%) only.
PRPH' s Operating margin (%) Range Over the Past 10 Years
Min: -35.47  Med: -16.54 Max: 1.66
Current: -15.68
-35.47
1.66
Net-margin (%) -16.47
PRPH's Net-margin (%) is ranked lower than
80% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.71 vs. PRPH: -16.47 )
Ranked among companies with meaningful Net-margin (%) only.
PRPH' s Net-margin (%) Range Over the Past 10 Years
Min: -35.5  Med: -16.5 Max: 1.62
Current: -16.47
-35.5
1.62
ROE (%) -45.24
PRPH's ROE (%) is ranked lower than
87% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.47 vs. PRPH: -45.24 )
Ranked among companies with meaningful ROE (%) only.
PRPH' s ROE (%) Range Over the Past 10 Years
Min: -67.21  Med: -23.05 Max: 3.37
Current: -45.24
-67.21
3.37
ROA (%) -26.77
PRPH's ROA (%) is ranked lower than
83% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. PRPH: -26.77 )
Ranked among companies with meaningful ROA (%) only.
PRPH' s ROA (%) Range Over the Past 10 Years
Min: -46.8  Med: -14.78 Max: 2.38
Current: -26.77
-46.8
2.38
ROC (Joel Greenblatt) (%) -44.14
PRPH's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. PRPH: -44.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRPH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -145.68  Med: -68.79 Max: 5.51
Current: -44.14
-145.68
5.51
Revenue Growth (3Y)(%) -6.00
PRPH's Revenue Growth (3Y)(%) is ranked lower than
78% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. PRPH: -6.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRPH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.5  Med: -4.5 Max: 124.2
Current: -6
-32.5
124.2
EBITDA Growth (3Y)(%) 50.90
PRPH's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.50 vs. PRPH: 50.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRPH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.4  Med: -3.8 Max: 52
Current: 50.9
-47.4
52
EPS Growth (3Y)(%) 46.50
PRPH's EPS Growth (3Y)(%) is ranked higher than
89% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. PRPH: 46.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRPH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.9  Med: 14.4 Max: 88.2
Current: 46.5
-41.9
88.2
» PRPH's 10-Y Financials

Financials (Next Earnings Date: 2017-03-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PRPH Guru Trades in Q4 2015

Jim Simons 95,200 sh (+9.43%)
» More
Q1 2016

PRPH Guru Trades in Q1 2016

Jim Simons 98,400 sh (+3.36%)
» More
Q2 2016

PRPH Guru Trades in Q2 2016

Jim Simons 100,300 sh (+1.93%)
» More
Q3 2016

PRPH Guru Trades in Q3 2016

Jim Simons 106,700 sh (+6.38%)
» More
» Details

Insider Trades

Latest Guru Trades with PRPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:NVGN, AMEX:AXN, OTCPK:CHEXF, OTCPK:INNV, NAS:IMNP, NAS:ALQA, NAS:TNXP, OTCPK:SUWN, AMEX:CPHI, OTCPK:ATHJF, OTCPK:INBP, OTCPK:ECTE, AMEX:NNVC, NAS:ALIM, OTCPK:BIOYF, NAS:NBRV, NAS:OASM, OTCPK:DKNMF, NAS:ASMB, NAS:ZGNX » details
ProPhase Labs Inc is a manufacturer and distributor of homeopathic and health products. It is also engaged in the research & development of potential over-the-counter drug, natural health products, supplements, personal care & cosmeceutical products.

ProPhase Labs Inc is organized in Nevada in July 1989. The Company manufactures, markets and distributes homeopathic and health products that are offered to the general public. It also is engaged in the research and development of potential over-the-counter drug, natural base health products along with supplements, personal care and cosmeceutical products. It manufactures, distributes and markets over-the-counter cold remedy products to consumers through national chain, regional, specialty and local retail stores. Its flagship brand is Cold-EEZE Cold Remedy and its product is Cold-EEZE zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by 42%. In addition to Cold-EEZE Cold Remedy lozenges, the Company markets and distributes non-lozenge forms of zinc gluconate formulations: Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray. The Company expanded its Cold-EEZE Cold Remedy QuickMelts product line and shipped two products: Cold-EEZE Plus Immune Support QuickMelts and Cold-EEZE Plus Immune Support + Energy QuickMelts to retailers in July 2013. The company acquired manufacturing and distribution rights to its lozenge formulation in 1992 and commenced national marketing in 1996. The Company maintains trademarks for its products including Cold-EEZE, Kinds-EEZE, QuickMelts, Organix Rx Complete and Organix Rx Defense. The company is subject to federal and state laws and regulations adopted for the health and safety of users of pharmaceutical and health care products.

Ratios

vs
industry
vs
history
P/B 5.19
PRPH's P/B is ranked lower than
75% of the 953 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. PRPH: 5.19 )
Ranked among companies with meaningful P/B only.
PRPH' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 2.44 Max: 7.14
Current: 5.19
0.87
7.14
P/S 1.55
PRPH's P/S is ranked higher than
70% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. PRPH: 1.55 )
Ranked among companies with meaningful P/S only.
PRPH' s P/S Range Over the Past 10 Years
Min: 0.61  Med: 1.24 Max: 4.46
Current: 1.55
0.61
4.46
Current Ratio 1.56
PRPH's Current Ratio is ranked lower than
70% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. PRPH: 1.56 )
Ranked among companies with meaningful Current Ratio only.
PRPH' s Current Ratio Range Over the Past 10 Years
Min: 1.43  Med: 3.22 Max: 24.11
Current: 1.56
1.43
24.11
Quick Ratio 0.89
PRPH's Quick Ratio is ranked lower than
79% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. PRPH: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
PRPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.68 Max: 19.63
Current: 0.89
0.8
19.63
Days Inventory 151.00
PRPH's Days Inventory is ranked lower than
66% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.87 vs. PRPH: 151.00 )
Ranked among companies with meaningful Days Inventory only.
PRPH' s Days Inventory Range Over the Past 10 Years
Min: 97.5  Med: 131.84 Max: 165.11
Current: 151
97.5
165.11
Days Sales Outstanding 64.87
PRPH's Days Sales Outstanding is ranked higher than
60% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.59 vs. PRPH: 64.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.87  Med: 83.23 Max: 121.34
Current: 64.87
64.87
121.34
Days Payable 68.03
PRPH's Days Payable is ranked lower than
54% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.65 vs. PRPH: 68.03 )
Ranked among companies with meaningful Days Payable only.
PRPH' s Days Payable Range Over the Past 10 Years
Min: 17.15  Med: 33.11 Max: 68.03
Current: 68.03
17.15
68.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
PRPH's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 434 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.70 vs. PRPH: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.5  Med: -3.1 Max: 5.7
Current: -2.8
-29.5
5.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.90
PRPH's Price/Net Current Asset Value is ranked lower than
63% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. PRPH: 9.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRPH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.47  Med: 3.96 Max: 12.88
Current: 9.9
0.47
12.88
Price/Tangible Book 5.21
PRPH's Price/Tangible Book is ranked lower than
65% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. PRPH: 5.21 )
Ranked among companies with meaningful Price/Tangible Book only.
PRPH' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.42  Med: 2.94 Max: 11.21
Current: 5.21
0.42
11.21
Price/Median PS Value 1.25
PRPH's Price/Median PS Value is ranked lower than
60% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. PRPH: 1.25 )
Ranked among companies with meaningful Price/Median PS Value only.
PRPH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.34 Max: 5.46
Current: 1.25
0.39
5.46
Earnings Yield (Greenblatt) (%) -9.62
PRPH's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 1015 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. PRPH: -9.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRPH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.81  Med: 1.3 Max: 2.5
Current: -9.62
-9.81
2.5

More Statistics

Revenue (TTM) (Mil) $21.57
EPS (TTM) $ -0.21
Beta0.10
Short Percentage of Float0.16%
52-Week Range $1.08 - 2.24
Shares Outstanding (Mil)17.08
» More Articles for PRPH

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 Nov 23 2016
PROPHASE LABS, INC. Financials Nov 22 2016
PROPHASE LABS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 17 2016
ProPhase Labs Reports Arbitration Decision In Phusion Laboratories/Phosphagenics Dispute Nov 16 2016
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 15 2016
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report Nov 15 2016
ProPhase Labs Reports Financial Results for the Three Months and Nine Months Ended September 30,... Nov 14 2016
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
ProPhase Labs to Release Second Quarter 2016 Results on Tuesday, August 9th Aug 10 2016
ProPhase Labs to Release Second Quarter 2016 Results on Tuesday, August 9 th Aug 10 2016
ProPhase Labs Reports Financial Results for the Three Months and Six Months Ended June 30, 2016;... Aug 10 2016
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 10 2016
ProPhase Labs Reports Financial Results for the Three Months and Six Months Ended June 30, 2016;... Aug 09 2016
ProPhase Labs to Release Second Quarter 2016 Results on Tuesday, August 9th Aug 05 2016
ProPhase Labs, Inc. :PRPH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 Jun 01 2016
PROPHASE LABS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 26 2016
ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2016 May 16 2016
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report May 13 2016
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)